Core Insights - The U.S. FDA has granted Fast Track Designation to PLX-200 for treating Late-Infantile Neuronal Ceroid Lipofuscinosis (LINCL/CLN2 disease), marking a significant regulatory milestone for Polaryx Therapeutics [1][3] Company Overview - Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for rare pediatric lysosomal storage disorders (LSDs) [6] - Founded in 2014, the company aims to deliver safe and effective treatments that address the underlying pathophysiology of these diseases [6][7] Product Development - PLX-200, the lead drug candidate, is an orally available compound derived from gemfibrozil, which is FDA-approved for lipid regulation [4] - The drug's ability to cross the blood-brain barrier has been documented, potentially addressing significant unmet needs in multiple rare LSDs [4][7] Clinical Trials - The SOTERIA Phase 2 trial is designed to evaluate the safety, tolerability, and clinical activity of PLX-200 across four LSDs: CLN2, CLN3, Krabbe disease, and Sandhoff disease [5] - The trial is set to begin in the third quarter of 2026, with sites in the U.S., Europe, and Asia [5] - SOTERIA will incorporate analyses comparing treated arms to natural history data as a control, enhancing the robustness of the trial [5]
Polaryx Therapeutics Receives FDA Fast Track Designation for PLX‑200 for Late‑Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease)